{
  "source": "PA-Notification-Harvoni.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1146-15\nProgram Prior Authorization/Notification\nMedication Harvoni® (ledipasvir/sofosbuvir)\nP&T Approval Date 10/2014, 2/2015, 8/2015, 11/2015, 12/2016, 12/2017, 12/2018, 2/2019,\n2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nHarvoni® (ledipasvir/sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus\n(HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor,\nand is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric\npatients 3 years of age or older.\n• Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis\n• Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin\n• Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with\ncompensated cirrhosis, in combination with ribavirin.\n2. Coverage Criteriaa:\nA. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve Patients without Cirrhosis and have\na pre-treatment HCV RNA less than 6 million IU/mL:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\nb. Patient has a pre-treatment HCV RNA less than 6 million IU/mL\n-AND-\nc. Patient is without cirrhosis\n-AND-\nd. Patient is treatment naïve [patient has not experienced treatment failure (defined as viral\nrelapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon\n+/- ribavirin based regimen with or without an HCV protease inhibitor (e.g., Incivek,\nOlysio, Victrelis) or Sovaldi (sofosbuvir)]\n-AND-\ne. Patient is not receiving Harvoni in combination with another HCV direct acting\n© 2025 UnitedHealthcare Services, Inc.\n1\nantiviral agent [e.g., Sovaldi (sofosbuvir)]\nAuthorization will be issued for 8 weeks.\nB. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve Patients without Cirrhosis and have\na pre-treatm",
    "es, Inc.\n1\nantiviral agent [e.g., Sovaldi (sofosbuvir)]\nAuthorization will be issued for 8 weeks.\nB. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve Patients without Cirrhosis and have\na pre-treatment HCV RNA equal to or greater than 6 million IU/mL:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\nb. Patient has a pre-treatment HCV RNA equal to or greater than 6 million IU/mL\n-AND-\nc. Patient is without cirrhosis\n-AND-\nd. Patient is treatment naïve [patient has not experienced treatment failure (defined as viral\nrelapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon\n+/- ribavirin based regimen with or without an HCV protease inhibitor (e.g., Incivek,\nOlysio, Victrelis) or Sovaldi (sofosbuvir)]\n-AND-\ne. Patient is not receiving Harvoni in combination with another HCV direct acting\nantiviral agent [e.g., Sovaldi (sofosbuvir)]\nAuthorization will be issued for 12 weeks.\nC. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve Patients with Compensated\nCirrhosis:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\nb. Patient has compensated cirrhosis (e.g., Child-Pugh A)\n-AND-\nc. Patient is treatment naïve [patient has not experienced treatment failure (defined as viral\nrelapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon\n© 2025 UnitedHealthcare Services, Inc.\n2\n+/- ribavirin based regimen with or without an HCV protease inhibitor (e.g., Incivek,\nOlysio, Victrelis) or Sovaldi (sofosbuvir)]\n-AND-\nd. Patient is not receiving Harvoni in combination with another HCV direct acting\nantiviral agent [e.g., Sovaldi (sofosbuvir)]\nAuthorization will be issued for 12 weeks.\nD. Chronic Hepatitis C - Genotype 1 - Treatment-Experienced Patients without Cirrhosis:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepati",
    "for 12 weeks.\nD. Chronic Hepatitis C - Genotype 1 - Treatment-Experienced Patients without Cirrhosis:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\nb. Patient has experienced failure with a previous treatment regimen of a peginterferon\nalfa +/- ribavirin based regimen with or without an HCV protease inhibitor (e.g.,\nIncivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)\n-AND-\nc. Patient is without cirrhosis\n-AND-\nd. Patient is not receiving Harvoni in combination with another HCV direct acting\nantiviral agent [e.g., Sovaldi (sofosbuvir)]\nAuthorization will be issued for 12 weeks.\nE. Chronic Hepatitis C - Genotype 1 - Treatment-Experienced Patients with Compensated\nCirrhosis:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\nb. Patient has experienced failure with a previous treatment regimen that included either\npeginterferon alfa +/- ribavirin based regimen with or without an HCV protease\ninhibitor (e.g., Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n3\nc. Patient has compensated cirrhosis (e.g., Child-Pugh A)\n-AND-\nd. Patient is without decompensated liver disease (e.g., Child-Pugh B or C)\n-AND-\ne. One of the following:\n(1) Patient will receive Harvoni in combination with ribavirin\n-OR-\n(2) Patient is not eligible for ribavirin\n-AND-\nf. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\nIn combination with ribavirin: Authorization will be issued for 12 weeks.\nIneligible for ribavirin: Authorization will be issued for 24 weeks.\nF. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve or Treatment-Experienced\nPatients with Decompensated Cirrhosis:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\nb. Patient h",
    "tment-Experienced\nPatients with Decompensated Cirrhosis:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\nb. Patient has decompensated liver disease (e.g., Child-Pugh B or C)\n-AND-\nc. Patient will receive Harvoni in combination with ribavirin\n-AND-\nd. Patient is not receiving Harvoni in combination with another HCV direct acting\nantiviral agent [e.g., Sovaldi (sofosbuvir)]\nAuthorization will be issued for 12 weeks.\nG. Chronic Hepatitis C - Genotype 4, 5 or 6 - Treatment-Naïve or Treatment-Experienced\n© 2025 UnitedHealthcare Services, Inc.\n4\nPatients without Cirrhosis or with Compensated Cirrhosis:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 4, 5 or 6 infection\n-AND-\nb. One of the following:\n(1) Patient is without cirrhosis\n-OR-\n(2) Both of the following:\n(a) Patient has compensated cirrhosis (e.g., Child-Pugh A)\n-AND-\n(b) Patient is without decompensated liver disease (e.g., Child-Pugh B or C)\n-AND-\nc. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\nAuthorization will be issued for 12 weeks.\nH. Chronic Hepatitis C - Genotype 1 or 4 - Treatment-Naïve or Treatment-Experienced Liver\nTransplant Recipients without Cirrhosis or with Compensated Cirrhosis:\n1. Harvoni will be approved based on all of the following criteria:\na. Diagnosis of chronic hepatitis C genotype 1 or 4 infection\n-AND-\nb. Patient has previously received a liver transplant\n-AND-\nc. One of the following:\n(1) Patient is without cirrhosis\n-OR-\n© 2025 UnitedHealthcare Services, Inc.\n5\n(2) Both of the following:\n(a) Patient has compensated cirrhosis (e.g., Child-Pugh A)\n-AND-\n(b) Patient is without decompensated liver disease (e.g., Child-Pugh B or C)\n-AND-\nd. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n-AN",
    "s without decompensated liver disease (e.g., Child-Pugh B or C)\n-AND-\nd. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n-AND-\ne. Patient will receive Harvoni in combination with ribavirin\nAuthorization will be issued for 12 weeks.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• Medical necessity may be in place.\n4. References:\n1. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of\nAmerica. Recommendations for Testing, Managing, and Treating Hepatitis C.\nhttp://www.hcvguidelines.org/full-report-view. Accessed December 19, 2024.\nProgram Prior Authorization/Notification - Harvoni™ (ledipasvir/sofosbuvir)\nChange Control\n10/2014 New program.\n10/2014 Separated criteria sections to address treatment-naïve patients without\ncirrhosis and pre-treatment HCV RNA equal to or greater than 6 million\nIU/mL from the treatment-naïve patients with cirrhosis separately.\n2/2015 Added Sovaldi as part of prior treatment criterion. Added criterion to\nprevent combination therapy.\n8/2015 Added criteria for genotype 4 infection.\n11/2015 Added genotype 5 and 6 based updated FDA approval.\n© 2025 UnitedHealthcare Services, Inc.\n6\n12/2016 Added criteria for genotype 1 patients with decompensated cirrhosis.\nUpdated genotype 1 treatment experienced criteria to include compensated\ncirrhosis only. Added c",
    "ealthcare Services, Inc.\n6\n12/2016 Added criteria for genotype 1 patients with decompensated cirrhosis.\nUpdated genotype 1 treatment experienced criteria to include compensated\ncirrhosis only. Added criteria for post liver transplant genotype 1 or 4\npatients per updated FDA label. Updated references.\n12/2017 Annual review with no change to clinical coverage criteria. Updated\nreferences.\n12/2018 Annual review with no change to clinical coverage criteria. Updated\nreferences.\n2/2019 Updated references and removed Olysio from examples.\n2/2020 Annual review. Added additional background information. Updated\ngenotype 1 treatment-naïve criteria to include compensated cirrhosis only.\nUpdated genotype 1 treatment experienced criteria treatment regimen and\nduration. Updated references.\n2/2021 Annual review. Removed Olysio from list of examples for HCV direct\nacting antiviral agent with no change to clinical intent. Updated references\n2/2022 Annual review with no changes to coverage criteria. Updated references.\n2/2023 Annual review. Revised coverage criteria for Genotype 1 treatment-\nexperienced patients with compensated cirrhosis per FDA label. Added\nstate mandate and updated references.\n2/2024 Annual review. Added cirrhosis criteria for treatment of chronic hepatitis C\n- genotype 4, 5 or 6.\n2/2025 Annual review with no changes to coverage criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n7"
  ]
}